A novel, intelligent, system for remote patient monitoring of asthma and COPD using fast response capnography

世界卫生组织估计，地球上超过7%的人口患有两种慢性呼吸道疾病：哮喘和慢性阻塞性肺病（COPD）。由于全球空气污染和吸烟的增加，世界范围内的发病率正在上升。现有的临床技术缺乏精确性、预测能力和可用性，无法提供持续的现实影响，导致了巨大的护理差距。因此，三分之二的哮喘死亡是可以预防的，三分之二的COPD患者未被诊断出来。哮喘和COPD每年给英国经济造成50亿英镑的损失，而美国经济每年损失超过1000亿美元。剑桥呼吸创新有限公司（CRIL）是一家风险投资支持的呼吸智能公司，于2013年在英国剑桥成立。我们的使命是通过准确的早期诊断、智能远程监测和早期预测恶化来改变呼吸医学。我们的N-Tida技术建立在新型、受专利保护的快速响应CO2传感器技术的基础上。目前临床使用的二氧化碳检测仪基于粗糙的低分辨率CO2传感器，通常集成到呼吸机中，旨在为临床医生提供关于呼吸的非常基本的信息，例如，呼吸速率和呼吸结束时呼出的最大CO2。我们的传感器提供无与伦比的灵敏度，高分辨率，直接从口腔采样。我们的传感器的灵敏度使以前从未见过的信息，编码在二氧化碳波形的形状，与肺生理学，这是没有其他技术在临床使用今天可以检测。我们已经开发了80种新的呼吸生物标志物，在过去6年中通过多项临床试验进行了验证，这些生物标志物提供了有关肺部健康的新信息，对哮喘和COPD患者气道阻塞的微小变化敏感。这些生物标志物推动了我们的人工智能诊断、监测和预测软件技术。

The WHO estimates that over 7% of the Earth's population suffer from two chronic respiratory conditions: asthma and chronic obstructive pulmonary disease (COPD). The incidence is rising worldwide due to global increases in air pollution and tobacco smoking. Existing clinical technologies lack the precision, predictive power and usability to deliver sustained real-world impact, resulting in a large care gap. As a result, two thirds of asthma deaths are preventable, and two thirds of patients with COPD are undiagnosed. Asthma and COPD costs the UK economy £5bn each year, and the US economy more than $100bn each year. Cambridge Respiratory Innovations Limited (CRIL) is a venture-backed respiratory intelligence company, founded in 2013 in Cambridge UK. Our mission is to transform respiratory medicine, through accurate early diagnostics, intelligent remote monitoring, and early prediction of deterioration. Our N-Tida technologies are built on a foundation of novel, patent-protected, fast-response CO2 sensor technology. Capnometers in clinical use today are based on crude, low-resolution CO2 sensors, often integrated into ventilators, designed to provide very basic information about breathing to clinicians, e.g., breathing rate, and maximum exhaled CO2 at the end of the breath. Our sensors provide unparalleled sensitivity, high resolution, sampled directly from the mouth. The sensitivity of our sensor enables never-before-seen information, encoded within the shape of the CO2 waveform, related to lung physiology, which no other technology in clinical use today can detect. We have developed 80 novel respiratory biomarkers, validated through several clinical trials over the past 6 years, which provide novel information about lung health, sensitive to small changes in airway obstruction in patients with asthma and COPD. These biomarkers drive our AI-powered diagnostic, monitoring and predictive software technologies.